1. Academic Validation
  2. Generation of binder-format-payload conjugate-matrices by antibody chain-exchange

Generation of binder-format-payload conjugate-matrices by antibody chain-exchange

  • Nat Commun. 2024 Oct 31;15(1):9406. doi: 10.1038/s41467-024-53730-3.
Vedran Vasic # 1 Steffen Dickopf # 1 2 Nadine Spranger 1 3 Rose-Sophie Rosenberger 1 Michaela Fischer 1 Klaus Mayer 1 Vincent Larraillet 1 Jack A Bates 1 Verena Maier 1 Tatjana Sela 1 Bianca Nussbaum 1 Harald Duerr 1 Stefan Dengl 1 Ulrich Brinkmann 4
Affiliations

Affiliations

  • 1 Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich, Penzberg, Germany.
  • 2 Veraxa Biotech, Heidelberg, Germany.
  • 3 Institute of Molecular Immunology, School of Medicine and Health, Technical University Munich (TUM), Munich, Germany.
  • 4 Roche Pharma Research and Early Development (pRED), Large Molecule Research (LMR), Roche Innovation Center Munich, Penzberg, Germany. ulrich.brinkmann@roche.com.
  • # Contributed equally.
Abstract

The generation of antibody-drug conjugates with optimal functionality depends on many parameters. These include binder epitope, antibody format, linker composition, conjugation site(s), drug-to-antibody ratio, and conjugation method. The production of matrices that cover all possible parameters is a major challenge in identifying optimal antibody-drug conjugates. To address this bottleneck, we adapted our Format Chain Exchange technology (FORCE), originally established for bispecific Antibodies, toward the generation of binder-format-payload matrices (pair-FORCE). Antibody derivatives with exchange-enabled Fc-heterodimers are combined with payload-conjugated Fc donors, and subsequent chain-exchange transfers payloads to antibody derivatives in different formats. The resulting binder-format-conjugate matrices can be generated with cytotoxic payloads, dyes, haptens, and large molecules, resulting in versatile tools for ADC screening campaigns. We show the relevance of pair-FORCE for identifying optimal HER2-targeting antibody-drug conjugates. Analysis of this matrix reveals that the notion of format-defines-function applies not only to bispecific Antibodies, but also to antibody-drug conjugates.

Figures
Products